target directory

osteoporosis clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT06414616

Source recordAI-normalized

Are We Overly Concerned About Rebound Fractures? Real-World Evidence of Adherence to Denosumab Therapy and Fracture Risk Associated With Drug Withdrawal: A Cross-sectional Study

This study investigates the adherence to Denosumab therapy and the associated fracture risk upon discontinuation, particularly during the COVID-19 pandemic. It aims to provide real-world evidence on the implications of treatment compliance and the potential rebound effect on fracture risk in osteoporosis patients.

AI analysis

Indication: Osteoporosis

Modality: monoclonal antibody

Target: Osteoporosis

Sponsor: Trakya University

Source URL: ClinicalTrials.gov

Source updated: May 16, 2024

Ingested: Jun 04, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Osteoporosis

View original source fields

Condition raw: Osteoporosis

Condition normalized: Osteoporosis

Modality raw: Detailed source ingestion pending

Modality normalized: monoclonal antibody

Target raw: Osteoporosis

Target normalized: Osteoporosis

Open report

NCT02166437

Source recordAI-normalized

Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study

This clinical trial investigates the efficacy of bisphosphonate and denosumab therapies following teriparatide treatment in Japanese patients with severe osteoporosis. The study aims to analyze bone mineral density (BMD), bone turnover markers, and fracture prevention effects in a cohort of 500 patients.